Seres Therapeutics, Inc. — Director's Dealing 2021

Feb 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Seres Therapeutics, Inc. (MCRB)
CIK: 0001609809
Period of Report: 2021-02-04

Reporting Person: DesRosier Thomas (Chief Legal Officer and EVP)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-04	Stock Option (Right to Buy)	$26.34	A	100000	Acquired	2031-02-03	Common Stock (100000)	Direct

Footnotes

F1: The option will vest as to 25% of the shares on February 4, 2022. The remainder of the shares will vest in 12 equal quarterly installments thereafter.